Recombinant lactic acid bacteria as mucosal ...
Document type :
Article dans une revue scientifique
PMID :
Title :
Recombinant lactic acid bacteria as mucosal biotherapeutic agents
Author(s) :
Daniel, Catherine [Auteur correspondant]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Roussel, Yvonne [Auteur]
Université Henri Poincaré - Nancy 1 [UHP]
Kleerebezem, Michiel [Auteur]
Wageningen University and Research [Wageningen] [WUR]
NIZO [Ede, Netherlands]
Pot, Bruno [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Roussel, Yvonne [Auteur]
Université Henri Poincaré - Nancy 1 [UHP]
Kleerebezem, Michiel [Auteur]
Wageningen University and Research [Wageningen] [WUR]
NIZO [Ede, Netherlands]
Pot, Bruno [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Journal title :
Trends in biotechnology
Pages :
499-508
Publisher :
Elsevier
Publication date :
2011-10
ISSN :
0167-7799
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and ...
Show more >The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.Show less >
Show more >The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health.Show less >
Language :
Anglais
Peer reviewed article :
Oui
Audience :
Internationale
Popular science :
Non
Source :